A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as baricitinib in participants with systemic lupus erythematosus.
The results of this study are not yet available.
Your participation could last up to 34 weeks and include 10 visits to the study center
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have a diagnosis of Systemic Lupus Erythematosus (SLE) at least 24 weeks prior to screening
Participant must have active arthritis and/or active rash at randomization
Participant must not have active severe lupus nephritis
Participant must not have active severe central nervous system (CNS) lupus
Participant must not have started treatment with or adjusted the dose of an antimalarial or immunosuppressant within 12 weeks of starting the study
Participant must not have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to screening
Participant must not have started treatment with or adjusted the dose of nonsteroidal anti-inflammatory drugs (NSAIDs) (for which the NSAID use is intended for treatment of signs and symptoms of SLE) within 4 weeks of starting the study